NHS Framework for the North of England, Branded Medicine
Details
- Buyer
- NHS England
- Supplier(s)
30 suppliers
- AVENTIS PHARMA LIMITED
- Accord UK Ltd
- Amgen Ltd
- Astra Zeneca UK Limited
- Bayer Ltd
- Bristol-Myers Squibb Pharmaceuticals Ltd
- Celltrion Healthcare United Kingdom Ltd
- CST Pharma Limited
- Eli Lilly and Company Ltd
- GEDEON RICHTER (UK) LIMITED
- Gilead Sciences Ltd, 280 High Holborn
- GLAXOSMITHKLINE UK LIMITED
- Ipsen
- Janssen Cilag Ltd
- Merck Serono Limited
- MERCK SHARP & DOHME (UK) LIMITED
- Mylan
- Napp Pharmaceuticals Ltd
- Novo Nordisk Ltd
- Organon Pharmaceuticals UK Ltd
- Pfizer Liimted
- Roche Products Ltd
- Sandoz
- Swedish Orphan Biovitrum Ltd (Sobi UK Ltd)
- Takeda UK Limited
- Teva UK Ltd
- Thornton and Ross
- UCB Pharma Ltd
- UL Global Pharma
- Zentiva Pharma UK Ltd
- Value
- GBP 238,913,892
- Duration
- 2 years
- Topic
- Pharmaceutical products
- Published
- 1 March 2022
- Source
- uk:contracts_finder
Tender description
Offer reference number: CM/PHR/20/5600 CM/PHR/20/5600/01 - NHS Framework for the North of England, Branded Medicines -Tranche B - 1 March 2022 to 29 February 2024 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months CM/PHR/20/5600/02 - NHS Framework for the North of England, Branded Medicines - Annual Tranche Products. Period of framework: 1 March 2022 to 28 February 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months. CM/PHR/20/5600/03- NHS Framework for Insulin Aspart Biosimilar (Trurapi®), South of England - Period of framework: 1 March 2022 to 31 August 2022 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months. CM/PHR/20/5600/04 - NHS Framework for Insulin Aspart Biosimilar (Trurapi®), London - Period of framework: 1 March 2022 to 31 August 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/20/5600/05 - NHS Framework for Insulin Aspart Biosimilar (Trurapi®), Midlands and East - Period of framework: 1 March 2022 to 28 February 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.
Timeline
- Completed: Award published1 March 2022Current notice
- Completed: Award date1 March 2022
- Completed: Contract expiry date29 February 2024
About the buyer
NHS England is a public sector buyer in United Kingdom publishing tenders and awards on Stotles. Explore their procurement activity and find more opportunities like this one.
Relevant CPV codes
- 33600000 · Pharmaceutical products
Decision makers
Connect with the people behind this procurement.
| Contact name | Job title | Phone number | Work email |
|---|---|---|---|
| Head of Procurement | +44 •••• •••••• | ••••••••@nhs-england.gov | |
| Commercial Director | +44 •••• •••••• | ••••••••@nhs-england.gov | |
| Procurement Manager | +44 •••• •••••• | ••••••••@nhs-england.gov | |
| Category Lead | +44 •••• •••••• | ••••••••@nhs-england.gov | |
| Senior Buyer | +44 •••• •••••• | ••••••••@nhs-england.gov | |
| Contracts Manager | +44 •••• •••••• | ••••••••@nhs-england.gov |
6 similar open tenders
See more open tenders related to NHS Framework for the North of England, Branded Medicine.
- Open tender
IMP Manufacture, Labelling and Packaging DPS
- Open tender
CPH037 - Enhanced Services (Pharmacies)
- Open tender
Potassium iodide tablets 2024-2026
Related buyers
Buyers similar to NHS England.
- 455£2.1bn
- 367£249.3m
- 357£15.0bn
- 293£2.8bn
- 263£19.7bn
- 253£892.5m
- 246£509.3m
- 203£1.0bn
- 140£895.5m
- 115£59.6m
Win more public sector contracts
Track every UK and Ireland tender in one place — set up alerts, find decision-makers, and never miss an opportunity.
